Clearer labels needed on drugs containing animal products

Patients with specific dietary restrictions may be unwittingly taking medicines containing animal products, suggests an article published in BMJ today.

Dr Kinesh Patel and Dr Kate Tatham say most medications prescribed in primary care contain animal derived products and it is unclear whether they are suitable for vegetarians.

They call for improved labelling, similar to those on food, to help inform doctors, pharmacists and patients about the content of medicines. And they stress that concerned patients should not stop taking their medication without consulting their doctor first.

Specific dietary preferences regarding animal products in food are common in the general population. Influences such as religion, culture, economic status, environmental concern, food intolerances, and personal preferences all play a part in the foods that people choose to consume.

Yet many patients and doctors are unaware that commonly prescribed drugs contain animal products – and simply reading the list of ingredients will not make it clear whether the product meets the patient's dietary preferences.

Problem ingredients include lactose (often extracted using bovine rennet), gelatine (sourced from cows, pigs and occasionally fish) and magnesium stearate (traditionally sourced from cows, pigs and sheep) although some manufacturers now use vegetarian alternatives.

Last year a campaign to vaccinate children in Scotland against influenza was halted because of concern in the Muslim community about pork gelatine within the vaccine.

Even though the absolute levels of animal products in many medications are likely to be minimal, the authors say doctors need to consider this when prescribing "to avoid non-adherence, which is a major healthcare concern."

To ascertain the scale of the problem, they identified the 100 most commonly prescribed drugs in UK in January 2013. Of these, 73 contained one or more of lactose, gelatine, or magnesium stearate. But they found that information on the origins of the contents was difficult to obtain, unclear, inconsistently reported, and sometimes incorrect.

"Our data suggest that it is likely that patients are unwittingly ingesting medications containing with neither prescriber nor dispenser aware," they write.

They call for improved drug labelling, mirroring those standards advised for food. However, they acknowledge it is unlikely that any labelling standard could address all dietary requirements, "and the ultimate solution would be to eliminate animal derived products where possible from medications."

They point out that lactose is already produced by some manufacturers without using rennet, magnesium stearate can be made chemically without animal ingredients and vegetarian capsules to replace gelatine are already available.

"Although vegetarian friendly ingredients may be more expensive than those produced by traditional processes, the costs would diminish as production expanded and they would limit the exposure of to products they find unacceptable," they conclude.

More information: www.bmj.com/cgi/doi/10.1136/bmj.g401

add to favorites email to friend print save as pdf

Related Stories

The alternative to yogurt

Jan 05, 2014

Researchers at the Universitat Politècnica de València have obtained new products fermented with probiotic bacteria from grains and nuts - what is known as plant-based or vegetable "milks" - which are an ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments